Korea Unveils Financial Tool To Boost New Drug Development
This article was originally published in PharmAsia News
You may also be interested in...
Korea Launches Inter-agency Body To Stimulate Local R&D, Earmarks $440 Million For Program
SEOUL - The Korean government has set up an inter-ministry team to support local pharmaceutical companies develop globally competitive drugs. The team will offer R&D training for companies looking to diversify their generic pipelines with innovative products as well as some of the start-up cash needed for new R&D programs
Korea's Health Ministry Gets In The Act To Generate Korean Innovation For U.S. Markets
SEOUL - South Korea's Ministry of Health and Welfare has selected 21 Korean pharmaceutical manufacturers and 17 medical equipment firms to support these companies in the development of globally competitive new drugs, marketing efforts and U.S. FDA approvals needed for their advancement into the U.S. market
Early-Stage Idiopathic Pulmonary Fibrosis (IPF) Candidates Race to Phase III
Multiple IPF drugs are being rushed into Phase III based on early-stage signals of efficacy and safety presented at the ATS meeting. Scrip spoke with the University of Pittsburgh's Kevin Gibson about the candidates, trial design, combination therapy and limitations of current therapy.